Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, 6-Week Study Designed to Investigate the Effects of BDP HFA Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA) Axis When Administered in Adolescent and Adult Subjects (12 to 45 Years of Age) With Perennial Allergic Rhinitis (PAR)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Massachusetts
-
North Dartmouth, Massachusetts, United States, 02747
- Teva Clinical Study Site
-
-
Texas
-
New Braunfels, Texas, United States, 78130
- Teva Clinical Study Site
-
San Antonio, Texas, United States, 78229
- Teva Clinical Study Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed Consent
- Male or female subjects 12-45 years of age
- Documented history of perennial allergic rhinitis
- General good health
- Other criteria apply
Exclusion Criteria:
- History of physical findings of nasal pathology (within 60 days prior to Screening Visit 1)
- Participation in any investigational drug study 30 days preceding Screening Visit 1
- History of respiratory infection/disorder with 14 days preceding Screening Visit 1
- Use of any prohibited concomitant medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP.
During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
|
Placebo nasal aerosol administered daily for 42 days of treatment
Placebo prednisone capsule taken each day on the last 7 days of treatment
|
|
Experimental: BDP HFA 320 µg/day
Participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning for 6 weeks (42 days).
During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
|
Placebo prednisone capsule taken each day on the last 7 days of treatment
Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
Other Names:
|
|
Active Comparator: Prednisone
Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP.
During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.
|
Placebo nasal aerosol administered daily for 42 days of treatment
Prednisone 10 mg capsule taken each day on the last 7 days of treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The 24-hour Serum Cortisol Weighted Mean After 42 Days of Treatment
Time Frame: Day 0 (Baseline), Day 42
|
Geometric mean serum cortisol weighted mean values were calculated at baseline and after 6 weeks (42 days) of treatment.
The geometric mean ratio of week 6 / baseline is reported.
The primary outcome compares the BDP HFA and Placebo treatment arms.
The comparison of active control (Placebo/Prednisone) and Placebo treatment arms is an "other pre-specified" outcome.
|
Day 0 (Baseline), Day 42
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Sudeesh K. Tantry, Ph.D., Teva Branded Pharmaceutical Products R&D, Inc.
Publications and helpful links
General Publications
- Hampel FC, Ratner PH, Miller SD, Melchior A, Dunbar SA, Tantry SK, Dorinsky PM. Once-daily treatment with beclomethasone dipropionate hydrofluoroalkane nasal aerosol (320 mcg/d) is not associated with hypothalamic-pituitary-adrenal axis suppression in adolescent subjects with perennial allergic rhinitis. J Allergy Clin Immunol 2012; 129:AB188
- Ratner PH, Miller SD, Hampel FC, A, Dunbar SA, Tantry SK, Dorinsky PM (2011). BDP HFA Nasal Aerosol 320 μg Once Daily g Once Daily Is Not Associated with HPA-Axis Suppression in Subjects With Perennial Allergic Rhinitis. Ann Allergy Asthma Immunol. 107(11):A118.
- Ratner PH, Miller SD, Hampel FC Jr, Melchior A, Dunbar SA, Tantry SK. Once-daily treatment with beclomethasone dipropionate nasal aerosol does not affect hypothalamic-pituitary-adrenal axis function. Ann Allergy Asthma Immunol. 2012 Nov;109(5):336-41. doi: 10.1016/j.anai.2012.08.005.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Otorhinolaryngologic Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Perennial
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Anti-Asthmatic Agents
- Respiratory System Agents
- Prednisone
- Beclomethasone
Other Study ID Numbers
Other Study ID Numbers
- BDP-AR-304
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.